1-甲基吡咯-2-羰酰氯 | 26214-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-甲基吡咯-2-羰酰氯
• 中文别名: 1-甲基-1H-吡咯-2-羰酰氯；1-甲基-1H-吡咯-2-甲酰氯；1-甲基-1H-吡咯-2-酰氯；1-甲基吡咯-2-甲酰氯
• 英文名称: 1-methyl-pyrrole-2-carboxylic acid chloride
• 英文别名: 1-Methyl-1H-pyrrole-2-carbonyl chloride；1-Methylpyrrole-2-carbonyl chloride
• CAS: 26214-68-6
• 化学式: C₆H₆ClNO
• mdl: MFCD02094021
• 分子量: 143.573
• InChiKey: JOYDZQJINHJNPM-UHFFFAOYSA-N

物化性质

• 沸点：
  78 °C
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 闪点：
  72-74°C/10mm
• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会分解。请避免接触氧化物、水分或潮湿环境、碱性和高温。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S23,S26,S30,S36/37/39,S45,S8
• 危险类别码：
  R14,R34,R29
• 海关编码：
  2933990090
• 包装等级：
  II
• 危险品运输编号：
  UN 3265
• 储存条件：
  在干性保护气体中处理，并确保贮藏容器密封。将容器存放在阴凉、干燥处。

SDS

Name:	1-Methyl-1H-pyrrole-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	26214-68-6

Section 1 - Chemical Product MSDS Name:1-Methyl-1H-pyrrole-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
26214-68-6	1-Methyl-1H-pyrrole-2-carbonyl chlorid	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 26214-68-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 84 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H6ClNO
Molecular Weight: 143.57

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 26214-68-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-1H-pyrrole-2-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 26214-68-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 26214-68-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 26214-68-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基吡咯-2-羰酰氯 在 bis(η3-allyl-μ-chloropalladium(II)) 、 cesium fluoride 、 亚磷酸三乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 26.0h， 生成 2-hydroxy-1-(1-methyl-1H-pyrrol-2-yl)-2-phenyl-ethanone
  参考文献：
  名称：

  Heteroacylsilanes: synthesis and synthetic potentialities of new nucleophilic acylation agents

  摘要：

  DOI：

  10.1021/jo00201a029
• 作为产物：
  描述：

  2,2,2-三氯-1-(1-甲基-1H-吡咯-2-基)-乙酮 在 sodium hydroxide 、 草酰氯 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 1-甲基吡咯-2-羰酰氯
  参考文献：
  名称：

  Groot, J. A. de; Steen, R. van der; Fokkens, R., Recueil des Travaux Chimiques des Pays-Bas, 1982, vol. 101, # 6, p. 219 - 223

  摘要：

  DOI：

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• AZOLE INHIBITORS OF CYTOKINE PRODUCTION
  申请人：——

  公开号：US20010044445A1

  公开（公告）日：2001-11-22

  Compounds having the formula 1 are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 production inhibitors.

  具有以下化学式的化合物对于治疗由白细胞介素-2、白细胞介素-4或白细胞介素-5产生抑制剂预防或改善的疾病是有用的。
• [EN] C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINE C7-FLUOROSUBSTITUÉE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010017470A1

  公开（公告）日：2010-02-11

  The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种由结构式（A）表示的化合物，或其药学上可接受的盐。结构式（A）的变量在此处定义。还描述了包括结构式（A）化合物的药物组合物及其治疗用途。
• Expedient Iron-Catalyzed C−H Allylation/Alkylation by Triazole Assistance with Ample Scope
  作者：Gianpiero Cera、Tobias Haven、Lutz Ackermann

  DOI：10.1002/anie.201509603

  日期：2016.1.22

  for the iron‐catalyzed C−H allylation of arenes, heteroarenes, and alkenes with ample scope. The versatile catalyst also proved competent for site‐selective methylation, benzylation, and alkylation with challenging primary and secondary halides. Triazole‐assisted C−H activation proceeded chemo‐, site‐, and diastereo‐selectively, and the modular TAM directing group was readily removed in a traceless

  三唑的协助为广泛范围内的芳烃，杂芳烃和烯烃的铁催化的CHH烯丙基化的统一策略奠定了基础。事实证明，这种多功能催化剂还可胜任具有选择性的一级和二级卤化物的定点甲基化，苄基化和烷基化。三唑辅助的CH活化是化学，位点和非对映选择性的，在极温和的反应条件下，模块化TAM导向基团很容易以无痕方式除去。
• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009076140A1

  公开（公告）日：2009-06-18

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑和恶唑化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的应用方法。